Helus Pharma (NASDAQ: HELP) (Cboe CA: HELP), a clinical-stage pharmaceutical company focused on developing novel serotonergic agonists (NSAs), has appointed Dr. Ken Kramer, PhD, as senior vice president of medical affairs, effective immediately. The appointment signals the company's commitment to advancing its pipeline of NSAs, including HLP003 for major depressive disorder and HLP004 for generalized anxiety disorder, as it strengthens engagement with clinical and scientific stakeholders.
Dr. Kramer brings over 20 years of neuroscience-focused medical affairs leadership, having held senior roles at Bristol Myers Squibb, Karuna Therapeutics, and AbbVie. His expertise is expected to bolster Helus's efforts in developing proprietary NSAs—synthetic molecules designed to activate serotonin pathways believed to promote neuroplasticity. The company aims to address the large unmet need for individuals suffering from depression, anxiety, and other mental health conditions.
Helus Pharma is currently advancing HLP003, a proprietary NSA in Phase 3 clinical development for the adjunctive treatment of major depressive disorder, which has received Breakthrough Therapy Designation from the U.S. Food and Drug Administration. Additionally, HLP004 is in Phase 2 for generalized anxiety disorder. The company also maintains an extensive research portfolio of investigational NSAs.
The appointment comes as Helus Pharma seeks to improve the treatment landscape through NSAs that aim to provide durable improvements in mental health. The company operates in Canada, the United States, the United Kingdom, and Ireland. For more information, visit www.helus.com or follow the team on X, LinkedIn, YouTube, and Instagram.
The full press release is available at https://ibn.fm/FdEXH.
